# Quanterix

Quanterix is an Asset Manager based in Billerica, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Billerica, United States
- **Region:** North America
- **Address:** Billerica, MA, United States
- **Founded:** 2007
- **Assets under management:** Undisclosed
- **Website:** quanterix.com
- **LinkedIn:** https://www.linkedin.com/company/quanterix

## Regulatory record

- **Reports private funds:** No

## About

Quanterix was founded in 2007 by David Walt, a Tufts University chemist, and spun out of his academic lab with an exclusive license to the single-molecule array (Simoa) technology. Kevin Hrusovsky, a former PerkinElmer executive, joined as CEO in 2014 and took the company public on the Nasdaq in 2017. Walt’s work on fiber-optic microarrays forms the intellectual-property backbone — Quanterix instruments count individual enzyme-labeled protein molecules trapped in femtoliter-volume wells. The firm markets its Simoa HD-X and SR-X analyzers to pharmaceutical research teams running neurology, oncology, and immunology programs. Its core product is not a drug but a research-tool ecosystem — instruments, consumable kits, and contract services — that generates recurring revenue from assay sales. Confirmed users include Eli Lilly’s Alzheimer’s division, which relies on Simoa’s p-tau217 blood test to screen trial participants. Quanterix also operates an Accelerator Lab in Billerica that provides sample-testing services to biotechs without in-house Simoa capacity. Quanterix employs several hundred people, with its headquarters and laboratory footprint concentrated in Billerica, Massachusetts. It maintains no additional offices of record. In February 2024 the firm announced a strategic partnership with Johnson & Johnson’s Janssen unit to co-develop blood-based biomarker assays for Alzheimer’s disease diagnostics (per company press release, February 2024). Quanterix occupies an unusual position: it is a public life-sciences tools company that behaves like a precision-diagnostics platform. Its intellectual-property moat rests on the Simoa patent estate and a growing library of multiplexed assay kits. The successor-product line under development, the Simoa One platform, aims to consolidate high-throughput and high-sensitivity workflows into a single instrument, which would let reference labs run both clinical trials and routine testing on one machine.

## Sectors

- Digital Health

## People

- Kevin Hrusovsky — Chairman and Chief Executive Officer

## Questions

### What does Quanterix actually sell?

Quanterix sells a hardware-and-reagents platform called Simoa (single-molecule array). The product line includes the HD-X analyzer for research labs and the SR-X for smaller studies, along with consumable assay kits for proteins like p-tau217, NfL, and IL-6. Roughly half of revenue comes from recurring consumable sales and service contracts, with the remainder from instrument placements (per the firm's public filings, 2023). In recent years it has added an Accelerator Lab service that runs client samples on Quanterix instruments for a fee.

### Who are Quanterix's main customers?

Its customer base is concentrated in pharmaceutical R&D and academic research centers. Large biopharma clients use Simoa to measure blood-based biomarkers in clinical trials, particularly in Alzheimer’s disease. The firm has disclosed relationships with Eli Lilly, the National Institutes of Health, and various academic medical centers. In February 2024 it expanded into diagnostics through a partnership with Johnson & Johnson's Janssen unit.

### How does the Simoa technology work?

Simoa works by isolating individual protein molecules in microscopic wells and using enzyme amplification to generate a detectable fluorescent signal from a single molecule. Conventional ELISA measures signal in bulk solution across the entire well; Simoa effectively digitizes the measurement so that each molecule is counted individually. The approach achieves femtomolar-level sensitivity, which is roughly a thousand times more sensitive than standard immunoassays (per peer-reviewed literature, 2010-2020).

### What is Quanterix's competitive moat?

Quanterix's primary defensibility comes from its patent estate on single-molecule array technology, licensed from Tufts University, and the accumulated know-how in manufacturing ultra-sensitive consumable assay kits. The installed base of roughly 1,200 instruments creates a recurring-revenue stream from assay sales. Competitors in the ultrasensitive immunoassay space include Singulex and Meso Scale Discovery, but neither offers the same combination of fully automated workflow and sub-femtomolar sensitivity.

## Related profiles

- [Accredited Labs](https://altss.com/profile/accredited-labs)
- [DAT Freight & Analytics](https://altss.com/profile/dat-freight-and-analytics)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/quanterix-corporation

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology